Table 2. Clinical and tumor characteristics of the discovery cohort (n = 32).
| Characteristic | Number (%) | CNV (%) | P-value |
|---|---|---|---|
| Age | 0.465 | ||
| ≤ 18 months | 12 (37.5) | 2 (6.3) | |
| > 18 months | 20 (62.5) | 5 (15.6) | |
| Gender | 0.500 | ||
| boy | 16 (50) | 3 (9.4) | |
| girl | 16 (50) | 4 (12.5) | |
| INSS | 0.041 | ||
| non–stage 4 | 16 (50) | 1 (3.1) | |
| 4 | 16 (50) | 6 (18.8) | |
| Histology (INPC) | 0.003 | ||
| Favorable (FH) | 16 (50) | 0 (0) | |
| Unfavorable (UH) | 16 (50) | 7 (21.9) | |
| Distant Metastatic | 0.061 | ||
| + | 17 (53.1) | 6 (18.8) | |
| − | 15 (46.9) | 1 (3.1) | |
| Serum NSE | 0.389 | ||
| > 100 ng/mL | 19(59.4) | 5 (15.6) | |
| ≤ 100 ng/mL | 13(39.4) | 2 (6.3) |